McKesson slides as drug-distributor sentiment sours ahead of earnings

McKesson (MCK) is down 5.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a negative read-through from the U.S. drug-distribution group after a major peer posted a quarterly EPS miss and delivered an update that the market did not embrace. With McKesson scheduled to report earnings after the close on May 7, investors may also be de-risking and taking profits into the event.

Details:

A large pharmaceutical distributor peer released quarterly results on May 6 that included an adjusted EPS miss versus expectations and an updated full-year outlook, pressuring sentiment across the group.

McKesson is set to report its fiscal 2026 fourth-quarter results after market close on May 7, which can amplify pre-report positioning and volatility.

In its earnings release-date announcement, McKesson indicated it had reaffirmed its full-year fiscal 2026 outlook, leaving the stock more exposed to sector-wide moves rather than a fresh company-specific update.

This could also reflect short-term technical or positioning effects after a strong prior run, with investors focusing on margin sensitivity in large-scale drug distribution.

Sources:

McKesson Investor Relations, Reuters

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MCK Insider Trading Activity

$MCK insiders have traded $MCK stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $MCK stock by insiders over the last 6 months:

MICHELE LAU (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 3,028 shares for an estimated $2,980,567.
NAPOLEON B JR RUTLEDGE (SVP, Controller & CAO) has made 0 purchases and 2 sales selling 657 shares for an estimated $596,716.
MARIA MARTINEZ sold 349 shares for an estimated $328,012
THOMAS L RODGERS (EVP, Chief Strategy & BDO) sold 276 shares for an estimated $225,265
LEANN B SMITH (EVP & Chief HR Officer) sold 190 shares for an estimated $179,550

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$MCK Hedge Fund Activity

We have seen 890 institutional investors add shares of $MCK stock to their portfolio, and 842 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,692,991 shares (-77.7%) from their portfolio in Q4 2025, for an estimated $3,029,323,587
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,157,872 shares (-72.4%) from their portfolio in Q4 2025, for an estimated $949,790,822
PACER ADVISORS, INC. removed 562,998 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $461,821,629
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 478,159 shares (-12.2%) from their portfolio in Q4 2025, for an estimated $392,229,046
WINSLOW CAPITAL MANAGEMENT, LLC added 437,073 shares (+inf%) to their portfolio in Q4 2025, for an estimated $358,526,611
WELLINGTON MANAGEMENT GROUP LLP removed 403,053 shares (-65.1%) from their portfolio in Q4 2025, for an estimated $330,620,345
FMR LLC added 276,365 shares (+9.4%) to their portfolio in Q4 2025, for an estimated $226,699,445

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$MCK Government Contracts

We have seen $11,015,371,419 of award payments to $MCK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER: $1,184,200,532
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JULY: $1,118,034,560

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$MCK Congressional Stock Trading

Members of Congress have traded $MCK stock 8 times in the past 6 months. Of those trades, 6 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MCK stock by members of Congress over the last 6 months:

REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.
SENATOR MARKWAYNE MULLIN has traded it 3 times. They made 3 purchases worth up to $150,000 on 02/04, 01/05 and 0 sales.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/18 and 1 sale worth up to $15,000 on 12/19.
REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 12/02 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$MCK Analyst Ratings

Wall Street analysts have issued reports on $MCK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 04/28/2026

To track analyst ratings and price targets for $MCK, check out Quiver Quantitative's $MCK forecast page.

$MCK Price Targets

Multiple analysts have issued price targets for $MCK recently. We have seen 8 analysts offer price targets for $MCK in the last 6 months, with a median target of $1000.0.

Here are some recent targets:

Kevin Caliendo from UBS set a target price of $1000.0 on 04/22/2026
Elizabeth Anderson from Evercore ISI Group set a target price of $950.0 on 04/08/2026
Michael Cherny from B of A Securities set a target price of $1000.0 on 04/06/2026
Glen Santangelo from Barclays set a target price of $1050.0 on 02/18/2026
Lisa Gill from JP Morgan set a target price of $1107.0 on 02/10/2026
Stephen Baxter from Wells Fargo set a target price of $925.0 on 02/05/2026
Steven Valiquette from Mizuho set a target price of $885.0 on 02/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.